文献速递复苏、休克与脓毒症创伤与烧伤

创伤大输血风险患者早期给予四因子凝血酶原复合物的疗效与安全性:PROCOAG随机临床试验

Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01
一句话结论创伤大输血风险患者早期给予4F-PCC未减少24小时血制品消耗,反而增加血栓栓塞事件,不支持系统性使用。

PROCOAG试验为双盲、随机、安慰剂对照优效性研究,在法国12个一级创伤中心纳入327例有大量输血风险的创伤患者,随机接受4F-PCC 1 mL/kg(25 IU因子IX/kg)或生理盐水1 mL/kg静脉给药,均按欧洲创伤出血指南早期比例输血。主要终点24小时血制品总消耗量无显著组间差异(12 U vs 11 U,绝对差0.2 U,95%CI -2.99~3.33,P=0.72)。4F-PCC组至少1次血栓栓塞事件发生率35% vs 安慰剂组24%(绝对差11%,95%CI 1%~21%,RR 1.48,95%CI 1.04~2.10,P=0.03)。结论不支持在大量输血风险患者中系统性使用4F-PCC。

要点

  • 24小时血制品总消耗量:4F-PCC组中位12 U(IQR 5-19)vs 安慰剂组11 U(IQR 6-19),绝对差0.2 U(95%CI -2.99~3.33),P=0.72,无统计学或临床显著差异。
  • 血栓栓塞事件:4F-PCC组56例(35%)vs 安慰剂组37例(24%),绝对差11%(95%CI 1%~21%),RR 1.48(95%CI 1.04~2.10),P=0.03。
  • 4F-PCC组给药方案为1 mL/kg(25 IU因子IX/kg)静脉给药,安慰剂组为1 mL/kg生理盐水。
  • 所有患者均接受早期比例输血(浓缩红细胞:新鲜冰冻血浆比例1:1至2:1),并按欧洲创伤出血指南治疗。

适用人群与场景

  • 法国12个一级创伤中心连续纳入的有大量输血风险的创伤患者,年龄中位39岁(IQR 27-56),损伤严重度评分中位36(IQR 26-50,属严重创伤)。
  • 入院血乳酸中位4.6 mmol/L(IQR 2.8-7.4),院前动脉收缩压<90 mmHg者179/324例(59%),男性233例(73%),需快速止血控制者226例(69%)。

处置流程与药物剂量

  • 4F-PCC组:静脉给予1 mL/kg(25 IU因子IX/kg)4F-PCC;安慰剂组:静脉给予1 mL/kg生理盐水。
  • 所有患者接受早期比例输血,浓缩红细胞:新鲜冰冻血浆比例为1:1至2:1,并按欧洲创伤出血指南治疗。

研究设计与关键结果

  • 研究设计:双盲、随机、安慰剂对照优效性试验,2017年12月29日至2021年8月31日在法国12个一级创伤中心进行,随访于2021年8月31日完成。
  • 筛选4313例最高级别创伤激活患者,350例符合急诊纳入条件,327例随机分组,324例纳入分析(4F-PCC组164例,安慰剂组160例)。
  • 主要终点24小时血制品总消耗量:4F-PCC组中位12 U(IQR 5-19)vs 安慰剂组11 U(IQR 6-19),绝对差0.2 U(95%CI -2.99~3.33),P=0.72。
  • 安全性终点至少1次血栓栓塞事件:4F-PCC组56例(35%)vs 安慰剂组37例(24%),绝对差11%(95%CI 1%~21%),RR 1.48(95%CI 1.04~2.10),P=0.03。

证据类型、等级与局限

  • 证据类型:双盲、随机、安慰剂对照优效性试验(PROCOAG),ClinicalTrials.gov注册号NCT03218722。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:这些发现不支持在有大量输血风险的创伤患者中系统性使用4F-PCC。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Optimal transfusion strategies in traumatic hemorrhage are unknown. Reports suggest a beneficial effect of 4-factor prothrombin complex concentrate (4F-PCC) on blood product consumption.

OBJECTIVE: To investigate the efficacy and safety of 4F-PCC administration in patients at risk of massive transfusion.

DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized, placebo-controlled superiority trial in 12 French designated level I trauma centers from December 29, 2017, to August 31, 2021, involving consecutive patients with trauma at risk of massive transfusion. Follow-up was completed on August 31, 2021.

INTERVENTIONS: Intravenous administration of 1 mL/kg of 4F-PCC (25 IU of factor IX/kg) vs 1 mL/kg of saline solution (placebo). Patients, investigators, and data analysts were blinded to treatment assignment. All patients received early ratio-based transfusion (packed red blood cells:fresh frozen plasma ratio of 1:1 to 2:1) and were treated according to European traumatic hemorrhage guidelines.

MAIN OUTCOMES AND MEASURES: The primary outcome was 24-hour all blood product consumption (efficacy); arterial or venous thromboembolic events were a secondary outcome (safety).

RESULTS: Of 4313 patients with the highest trauma level activation, 350 were eligible for emergency inclusion, 327 were randomized, and 324 were analyzed (164 in the 4F-PCC group and 160 in the placebo group). The median (IQR) age of participants was 39 (27-56) years, Injury Severity Score was 36 (26-50 [major trauma]), and admission blood lactate level was 4.6 (2.8-7.4) mmol/L; prehospital arterial systolic blood pressure was less than 90 mm Hg in 179 of 324 patients (59%), 233 patients (73%) were men, and 226 (69%) required expedient hemorrhage control. There was no statistically or clinically significant between-group difference in median (IQR) total 24-hour blood product consumption (12 [5-19] U in the 4F-PCC group vs 11 [6-19] U in the placebo group; absolute difference, 0.2 U [95% CI, -2.99 to 3.33]; P = .72). In the 4F-PCC group, 56 patients (35%) presented with at least 1 thromboembolic event vs 37 patients (24%) in the placebo group (absolute difference, 11% [95% CI, 1%-21%]; relative risk, 1.48 [95% CI, 1.04-2.10]; P = .03).

CONCLUSIONS AND RELEVANCE: Among patients with trauma at risk of massive transfusion, there was no significant reduction of 24-hour blood product consumption after administration of 4F-PCC, but thromboembolic events were more common. These findings do not support systematic use of 4F-PCC in patients at risk of massive transfusion.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03218722.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Bouzat P, Charbit J, Abback PS, et al. Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial. JAMA. 2023. PMID: 36942533. doi:10.1001/jama.2023.4080

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。